Harnessing the Most Powerful Cells to Personalize Immune Medicine
The future of immune medicine holds promise for lasting and durable impact on many diseases; our high resolution systems are powering the development and further personalization of these curative medicines.
A personalized functional proteomics system for any lab.
The Products Driving Our Superpowered Biology
Proteomics, Reimagined to uniquely detect our most powerful cells.
The IsoLight: The entire ELISA proteomics workflow, sample to answer.
IsoSpeak Software: Same day visualizations and insights.
See how we can shift the paradigms in your programs
Enabling a New Era of Precision Medicine
New Publications View All
- Multi-omics resolves a sharp disease-state shift between mild and moderate COVID-19
- Changes in peripheral and local tumor immunity after neoadjuvant chemotherapy reshape clinical outcomes in patients with breast cancer
- Targeted Co-delivery of Tumor Antigen and α-Galactosylceramide to CD141+ Dendritic Cells Induces a Potent Tumor Antigen-Specific Human CD8+ T Cell Response in Human Immune System Mice
Through this research, we were able to highlight the important role a functionally versatile subpopulation of CAR-T cells may play in the fight against cancer. This could lead to new methods to optimize T-cell products.
The ability to easily perform single-cell proteomics provides a way to understand the complexity of the cellular response to immunotherapy and then to design and test new therapies to enhance efficacy.
We see potential in utilizing IsoPlexis’ single-cell system to help provide deeper resolution into the functional impacts of our therapeutics… This collaboration will enable us to apply the sensitivity of this solution to further our understanding of patient-specific responses to our immune therapies.
“MD Anderson, IsoPlexis Link T-Cell Functionality to Immunotherapy Response in AML.”
The ability of the IsoLight to provide detailed analyses from very few cells is key, given that we are limited to small sample quantities of blood.
Current assays that rely on a single-plex ELISA or even multiparametric flow cytometry don’t give you the level of resolution that the IsoPlexis platform can provide.
As a cancer research center with a key focus on CAR-T and other cell therapies, we feel that IsoPlexis will enable us to better characterize response and potentially predict whether cancer patients will respond to CAR-T therapy before treatment.
Quality assays are mainly descriptive with some objective parameters like cytokine production, cytotoxicity, and proliferation. Only recently, with PSI… can we start to differentiate products.
— Alan Kay
